ACE and chronic kidney disease: The FIDELITY pooled analysis went on to combine results from FIDELIO-DKD and FIGARO-DKD trials comprising 13,026 patients with a broad spectrum of CKD and T2DM, all treated of whom were receiving the manufacturers’ maximum stated dose of an ACE inhibitor or ARB therapy.